Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients

Open access
Marzullo, P., Daffara, T., Mele, C., Zavattaro, M., Ferrero, A., Caputo, M., Prodam, F., Aimaretti, G. · 2022 · Journal of Endocrinological Investigation

Abstract

Purpose: Registered trials and real-world evidence (RWE) studies provided evidence on the efficacy of once-weekly (OW) semaglutide on hyperglycaemia and cardiovascular risk factors as add-on or de-novo treatment in type 2 diabetes (T2D). Methods: In a retrospective analysis of electronic data files from 258 T2D patients, this RWE study aimed to explore the impact of OW semaglutide on biochemical and anthropometric outcomes after 6 and 12 months in patients receiving at least one prescription of OW semaglutide between September 2019 and May 2021. Results: During the study period, 154 and 56 consecutive patients completed the 6 and 12 months of OW semaglutide treatment. HbA1c levels decreased by -1.02±0.1% after 6 months and -1.1±0.1% after 12 months of OW semaglutide ( p <0.0001 for both). At these time-points, HbA1c values were <7% in 61% and 57% of cases. HbA1c reduction was greater in patients with higher baseline HbA1c levels and it occurred irrespective of gender, age, insulin therapy and complications. The residual number of cases with HbA1c ≥9% by the study end was low (5.3% vs 18.9% at baseline). Weight loss occurred in 73.5% and 78.1% of cases and, compared to baseline, it was ≥5% in 21.2- 25.4% and ≥10% in 6.8-18.2% after 6 and 12 months, respectively. Significant predictors of HbA1c reduction after 6 months of OW semaglutide treatment were baseline HbA1c ( p <0.0001), bodyweight reduction ( p <0.0001) and disease duration ( p <0.001), while baseline HbA1c was the only predictor of HbA1c response after 12 months ( p <0.0001). Reported adverse events were consistent with the known safety profile of semaglutide. Conclusions: Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40618-022-01799-2

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Baseline clinical features of TD2 patients included in the study. OW overweight, CVD cardiovascular disease
Fig. 1 Baseline clinical features of TD2 patients included in the study. OW overweight, CVD cardiovascular diseaseCC BY · PubMed Central
Fig. 2 Changes in HbA1c levels after 6 and 12 months of treatment with OW semaglutide in T2D patients stratified by glomerular filtration rate (eGFR CDK-EPI) uncontrolled for age, gender and disease duration. For a description of the results of the multivariate-controlled analysis see the text
Fig. 2 Changes in HbA1c levels after 6 and 12 months of treatment with OW semaglutide in T2D patients stratified by glomerular filtration rate (eGFR CDK-EPI) uncontrolled for age, gender and disease duration. For a description of the results of the multivariate-controlled analysis see the textCC BY · PubMed Central
Fig. 3 Correlation analyses between baseline HbA1c values and delta HbA1c reduction after 6 and 12 months of treatment with OW semaglutide (panel A); baseline BMI values and delta BMI reduction after 6 and 12 months of treatment with OW semaglutide (panel B); delta HbA1c and delta BMI variations after 6 and 12 months of treatment with OW semaglutide (panel C). Individual correlation coefficients and significance are reported in the figure
Fig. 3 Correlation analyses between baseline HbA1c values and delta HbA1c reduction after 6 and 12 months of treatment with OW semaglutide (panel A); baseline BMI values and delta BMI reduction after 6 and 12 months of treatment with OW semaglutide (panel B); delta HbA1c and delta BMI variations after 6 and 12 months of treatment with OW semaglutide (panel C). Individual correlation coefficients and significance are reported in the figureCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Cited by

See all 35

Metadata

Authors
Marzullo, P., Daffara, T., Mele, C., Zavattaro, M., Ferrero, A., Caputo, M., Prodam, F., & Aimaretti, G.
Affiliations
  • Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
  • Azienda Ospedaliero Universitaria Maggiore della Carita (IT)
Corresponding author
Marzullo, P.
Venue
Journal of Endocrinological Investigation
Published
2022-04-16
Volume
45
Issue
8
Pages
1587-1598
ISSN
  • 0391-4097 (ISSN-L)
  • 1720-8386
OpenAlex
W4224120703
Cited by
34
References
62
Citations by year
2026: 7 · 2025: 8 · 2024: 6 · 2023: 10 · 2022: 3
FWCI
5.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Endocrinological Investigation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Open access funding provided by Università degli Studi del Piemonte Orientale Amedeo Avogrado within the CRUI-CARE Agreement.
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
semaglutide, type 2 diabetes, HbA1c reduction, glycemic control, weight loss, GLP-1 receptor agonists, real-world evidence, predictors of treatment response, adverse events, Italian patients, insulin therapy, disease duration, cardiovascular risk factors, hyperglycemia, predictors of weight loss
MeSH terms
Semaglutide, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Retrospective Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients. https://app.cochat.ai/papers/10.1007/s40618-022-01799-2
The paper
Marzullo, P., Daffara, T., Mele, C., Zavattaro, M., Ferrero, A., Caputo, M., Prodam, F., & Aimaretti, G. (2022). Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-022-01799-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.